A detailed history of Black Rock Inc. transactions in Karyopharm Therapeutics Inc. stock. As of the latest transaction made, Black Rock Inc. holds 9,447,678 shares of KPTI stock, worth $8.22 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
9,447,678
Previous 10,071,677 6.2%
Holding current value
$8.22 Million
Previous $8.66 Million 64.7%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 10, 2024

SELL
$0.72 - $1.66 $449,279 - $1.04 Million
-623,999 Reduced 6.2%
9,447,678 $14.3 Million
Q4 2023

Feb 13, 2024

SELL
$0.68 - $1.31 $690,102 - $1.33 Million
-1,014,856 Reduced 9.15%
10,071,677 $8.66 Million
Q3 2023

Nov 13, 2023

SELL
$1.14 - $1.81 $513,852 - $815,853
-450,748 Reduced 3.91%
11,086,533 $14.9 Million
Q2 2023

Aug 11, 2023

BUY
$1.79 - $4.59 $4.41 Million - $11.3 Million
2,465,093 Added 27.17%
11,537,281 $20.7 Million
Q1 2023

May 12, 2023

BUY
$2.84 - $3.92 $1.6 Million - $2.21 Million
563,951 Added 6.63%
9,072,188 $35.3 Million
Q4 2022

Feb 13, 2023

BUY
$2.48 - $5.93 $1.48 Million - $3.53 Million
595,283 Added 7.52%
8,508,237 $28.9 Million
Q3 2022

Nov 14, 2022

SELL
$4.08 - $5.82 $856,371 - $1.22 Million
-209,895 Reduced 2.58%
7,912,954 $43.2 Million
Q2 2022

Aug 12, 2022

BUY
$4.15 - $8.37 $810,208 - $1.63 Million
195,231 Added 2.46%
8,122,849 $36.6 Million
Q1 2022

May 12, 2022

SELL
$5.91 - $14.38 $5.85 Million - $14.2 Million
-990,588 Reduced 11.11%
7,927,618 $58.4 Million
Q4 2021

Feb 10, 2022

BUY
$5.21 - $8.61 $666,296 - $1.1 Million
127,888 Added 1.45%
8,918,206 $57.3 Million
Q3 2021

Nov 09, 2021

BUY
$4.45 - $10.63 $40,361 - $96,414
9,070 Added 0.1%
8,790,318 $51.2 Million
Q2 2021

Aug 11, 2021

BUY
$8.11 - $11.11 $71.2 Million - $97.6 Million
8,781,248 New
8,781,248 $90.6 Million

Others Institutions Holding KPTI

About Karyopharm Therapeutics Inc.


  • Ticker KPTI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 79,806,600
  • Market Cap $69.4M
  • Description
  • Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases. The company discovers, develops, and commercializes novel and Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and in...
More about KPTI
Track This Portfolio

Track Black Rock Inc. Portfolio

Follow Black Rock Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.